Article History
Accepted: 17 December 2020
First Online: 22 February 2021
Compliance with Ethical Standards
:
: GM is a co-investigator with trials that utilize guselkumab and erlotinib. CAB has been a co-investigator or lead investigator for multiple trials, active ones which include guselkumab, erlotinib, and sulindac/DMFO. CM declares that she has no conflicts of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.